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with ICD-9 diagnosis codes for stroke/TIA had their diagnostic imaging utilization 
summarized within ±3 days of the stroke/TIA event. Results: A total of 18,770 
matched patients were identified; average age 65.5 (13.38 SD) and 21.9% female. 
When comparing patients that had at least one diagnostic procedure within the 
year, ICD patients had significantly less imaging overall [5.4 (6.38 SD) vs. 6.8 (8.18 
SD), p< 0.0001]. Among patients with records of stroke/TIA (ICD 5%, non-implant 
4%) and accompanying diagnostic imaging, 44% of non-implant patients underwent 
magnetic resonance imaging (MRI) vs. 1% of ICD patients (p< 0.0001) and had more 
imaging tests overall (4.1 (2.47 SD) vs. 3.2 (2.16 SD), p< 0.0001). ConClusions: MRI 
utilization is lower in ICD patients compared to non-implant patients. One in 20 ICD 
patients require imaging for a recorded stroke/TIA and less than 1% received MRI 
for this indication. The burden of incident stroke/TIA in contemporary ICD patients 
may justify consideration of MRI conditional devices in the majority of ICD patients.
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objeCtives: This study aimed to compare and evaluate the health-related quality of 
life (HRQOL) in Asian end-stage renal disease (ESRD) patients treated with continu-
ous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD) 
in Singapore. Methods: Data used in this study were from two cross-sectional 
surveys conducted between 2009 and 2013. Participants were recruited from the 
PD centers of Singapore General Hospital and National University Hospital. The 
inclusion criteria were ESRD patients who have been on PD for at least 3 months 
and at least 21-year-old. In both surveys, participants completed the Kidney Disease 
Quality of Life (KDQOL) instrument and questions assessing socio-demographic 
characteristics. Co-morbidities, clinical, and dialysis-related variables (i.e. vintage, 
dialysis adequacy, dependency status [self-cared/assisted]) were retrieved from 
medical records. The 36-item KDQOL (KDQOL-36) was used to generate two generic 
summary scores (physical component summary [PCS], mental component sum-
mary [MCS]), three disease-specific scales (symptoms, effects, burden), and two 
health utility scores (Short Form 6-Dimension [SF-6D] and EuroQol 5-Dimension 
[EQ-5D]). The HRQOL of patients treated with CAPD and APD measured by the above-
mentioned scales was compared using separate linear regression models with 
and without adjustment of variables collected. Results: Of the 382 PD patients 
approached, 266 were eligible and agreed to participate: 145 on CAPD (mean age: 60.8 
years; female: 54.5%) and 121 on APD (mean age: 57.4 years; female: 54.5%). Without 
adjustment, the HRQOL of CAPD and APD patients were similar according to all 
measures except for KDQOL symptoms (difference: 6.2, p< 0.01). With adjustments, 
significant differences were observed in KDQOL symptoms (7.0, p< 0.01) and PCS 
(2.8, p< 0.05) between CAPD and APD patients, suggesting that APD was associated 
with milder dialysis-related symptoms and better physical health. ConClusions: 
It appears that APD patients experience better HRQOL in some domains than CAPD 
patients in Singapore, although generic utility measures are not sensitive to this 
treatment advantage.
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objeCtives: This study aimed at assessing patient preferences for different char-
acteristics of Dry Powder Inhalers (DPIs) from patients with asthma and chronic 
obstructive pulmonary (COPD) disease in France. Methods: Attributes character-
izing DPIs and attribute levels were defined using focus groups among asthma and 
COPD patients and interviews of health care professionals, previously reported. 
Those attributes were ease of use, accurate and easy-to-read dose counter, dose 
confirmation, hygiene of the mouthpiece, flexibility of device handling and use with 
breathing difficulties. A survey was conducted among asthma and COPD patients to 
elicit patients’ preferences and willingness to pay using the discrete choice experi-
ment (DCE) method. A fractional factorial design including 3 sets of 12 choices was 
created. Each choice was made in two steps: a choice between two fictitious inhal-
ers then between preferred inhaler and current inhaler. Analyses were performed 
using a ranked ordered logit model. Interactions between attributes and asthma/
COPD were tested. Results: Participants included 201 patients with asthma and 60 
with COPD. Asthma patients were on average 40 years old and COPD patients were 
51 year old. Patients were willing to pay € 4.70 per month (standard error: € 0.49) for 
an inhaler requiring one step to prepare a dose instead of four, € 3.62 (€ 0.61) for an 
accurate dose counter compared to a less precise one, € 3.27 (€ 0.48) for an inhaler 
giving confirmation that the dose has been taken, € 1.02 (€ 0.38) for flexibility of han-
dling and € 4.79 (€ 0.73) to be able to use the inhaler in case of breathing difficulties. 
Preferences of patients with asthma and COPD are largely similar. ConClusions: 
Patients with asthma and COPD place highest values on the ease of use and abil-
effective. Screening of other immunocompromised populations is cost-prohibitive, 
however with minimal well-designed studies using consistent assumptions and 
parameters, these Conclusions should be interpreted cautiously.
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objeCtives: To estimate the cost attributed to productivity loss due to patient’s 
hospitalization, in patients subjected to pacemaker (PM) and implantable cardi-
overter-defibrillator (ICD) implantation. Methods: A single-center, prospective, 
cost-of-illness study was conducted for one year period. In total, 464 consecutive 
patients were recruited. 370 were subjected to PM implantation, (240 initials, 130 
replacements) and 94 to ICD (80 initials, 14 replacements). Data were assessed at 
patients’ enrolment in the study and at 6th and 12th months after the implanta-
tion. Then, the cost attributed to productivity loss due to patient’s hospitalization, 
was calculated using a bottom-up approach. Results: The mean (95% confidence 
interval) cost attributed to productivity loss for the PM recipients was found to be 
€ 39 (€ 25–€ 53). € 43 (€ 26–€ 64) for the patients who were subjected to initial implanta-
tion and € 30 (€ 12–€ 57) for the patients subjected to replacement. In one year follow 
up for the patients who were subjected to PM implantation the mean cost was € 71 
(€ 70–€ 72), € 71 (€ 70–€ 73) for the patients who were subjected to initial implantation 
and € 70 (€ 70–€ 70) for the patients subjected to replacement. For the ICD recipi-
ents was found to be € 186 (€ 119–€ 268), € 207 (€ 130–€ 303) for the patients who were 
subjected to initial implantation and € 53 (€ 0–€ 140) for the patients who were 
subjected to replacement. In one year follow up for ICD recipients the mean cost 
was € 367 (€ 72–€ 802), € 414 (€ 73–€ 926) for the patients who were subjected to initial 
implantation and € 70 (€ 70–€ 70) for the patients who were subjected to replace-
ment. ConClusions: The study provides unique data regarding the cost attrib-
uted to productivity loss of CRMD recipients in Greece. The mean cost attributed to 
productivity loss, in the case of ICD recipients is much higher than in PM recipients.
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objeCtives: Advances in ultrasound technology and training have made it possible 
for physicians to conduct detailed imaging studies in an office setting. Ultrasound 
images make it possible to visualize subclinical evidence of disease activity quickly 
and could contribute to prompt initiation of therapy in patients with rheumatoid 
arthritis (RA). The objectives of this study were to describe the use and cost of 
ultrasound in patients with a confirmed diagnosis of RA, in the United States, over 
the last decade. Methods: Patients were selected from a large national private 
insurance-claims database if they had at least 2 claims for ICD-9 code 714.xx at 
least 45 days apart and received Disease-Modifying Antirheumatic Drug therapy 
between 2002 and 2013. The CPT codes 7880-7882 were used to identify ultrasound 
procedures. Descriptive statistics were used and simple hypothesis tests per-
formed. Results: A cohort of 129,005 patients with RA was selected for this study. 
Patients who received ultrasounds were significantly (p < 0.01) more likely to be 
younger, female, have point-of-service insurance, and live outside the Midwest. 
Between 2002 and 2013, there was a > 1900% increase in the use of ultrasound in 
this patient population, from 73 procedures in 2002 to 1448 procedures in 2013. 
During this same period, the mean cost of the ultrasound procedure fluctuated 
over time; the cost increased 35% to a high of $216 (2013 USD) in 2008 and then 
decreased starting after 2010 down 32% by 2013 to $146 (2013 USD). Rheumatologists 
performed 70% of the procedures. ConClusions: This research clearly shows that 
use of ultrasound, primarily by rheumatologists, has been increasing. The data also 
show that patients who received ultrasounds may be different than those who did 
not receive the procedure. Further research is needed to evaluate the impact ultra-
sounds may have on treatment decisions, access to biologics, and patient outcomes.
PMD55
EVIDENCE Of A GAP IN CARE: uTILIzATION Of RADIOLOGIC DIAGNOSTIC 
IMAGING IN PATIENTS wITH AND wITHOuT IMPLANTAbLE DEfIbRILLATORS
Nazarian S.1, Reynolds M.R.2, Ryan M.P.3, Wolff S.D.4, Mollenkopf S.5, Turakhia M.P.6
1Johns Hopkins University School of Medicine, Baltimore, MD, USA, 2Harvard Clinical Research 
Institute, Boston, MA, USA, 3CTI Clinical Trial and Consulting Services, Cincinnati, OH, USA, 
4Carnegie Hill Radiology, New York, NY, USA, 5Medtronic, Inc., Mounds View, MN, USA, 6Stanford 
University, Stanford, CA, USA
objeCtives: We examined diagnostic imaging utilization across all medical 
conditions and in the case of acute stroke in patients with implantable cardio-
verter defibrillators (ICD) and a propensity matched cohort without record of any 
devices. Methods: This study used data from MarketScan® Commercial Claims 
and Medicare Supplemental database (Truven Health Analytics, New York, NY). 
Patients with continuous health plan enrollment in the calendar year 2012 with 
and without ICDs were identified. Patients in the ICD group were matched 1:1 using 
direct (age, gender and type of insurance plan) and propensity score matching 
(comorbid conditions) to patients with no record of device implantation. Diagnostic 
imaging utilization was compared across the matched cohorts, in total and by imag-
ing category, for the calendar year 2012. The same comparison was carried out 
for the stoke/TIA sub-population of interest. For the calendar year 2012, patients 
